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Unweighting, but not denervation, of muscle reportedly "spares" insulin receptors, increasing insulin sensitivity. Unweighting
also increases I_-adrenergic responses of carbohydrate metabolism. These differential characteristics were studied further by
comparing cyclic adenosine monophosphate (cAMP) accumulation and _-adrenergic binding in normal and 3-day unweighted
or denervated soleus muscle. Submaximal amounts of isoproterenol, a [3-agonist, increased cAMP accumulation in vitro and in
vivo (by intramuscular [IM] injection) to a greater degree (P < .05) in unweighted muscles. Forskolin or maximal isoproterenol
had similar in vitro effects in all muscles, suggesting increased _-adrenergic sensitivity following unweighting. Increased
sensitivity was confirmed by a greater receptor density (Bmax} for [12Sl]iodo-(-}-pindolol in particulate preparations of
unweighted (420.10 -is mol/mg muscle) than of control or denervated muscles (265.10 -18 mol/mg muscle). The three
dissociation constant (Kd) values were similar (20.3 to 25.8 pmol/L]. Total binding capacity (11.4 fmol/muscle) did not change
during 3 days of unweighting, but diminished by 30% with denervation. This result illustrates the "sparing" and loss of
receptors, respectively, in these two atrophy models. In diabetic animals, IM injection of insulin diminished cAMP accumulation
in the presence of theophylline in unweighted muscle (-66% -+ 2%} more than in controls (-42% -+ 6%, P < .001). These
results show that insulin affects cAMP formation in muscle, and support a greater in vivo insulin response following
unweighting atrophy. These various data support a role for lysosomal proteolysis in denervation, but not in unweighting,
atrophy.
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REVIOUS STUDIES from this laboratory demon-
strated enhanced insulin sensitivity of carbohydrate
metabolism in rat solcus muscle unwcightcd tic, weight-
bearing function rcmovcd) for 3 to 6 days. _-4 Increascd
insulin sensitivity was attributed to greater insulin-binding
capacity per milligram of muscle in the unweightcd soleus.
In contrast, dcnervation produces insulin resistance of
skeletal muscle carbohydrate metabolism, 5-7 associated with
a postreceptor defect and no alteration in insulin-binding
capacity. 5,8 Since membrane rcccptors may bc degraded via
the lysosomal pathway, _,I_ cnhanccd lysosomal proteolysis
in denervatcd, but not unweighted, solcus could account for
the contrasting cffccts of musclc atrophy on insulin-binding
capacity in these two models. 11 Rcccntly, wc extended thcsc
previous studies to the f3-adrcncrgic system, with the goal of
linking cnhanccd 13-adrcncrgic response to incrcascd mcm-
brahe-receptor binding. In parallel with heightened insulin
sensitivity, there is a greater rcsponsc of glycogen metabo-
lism to isoprotercnol, a 13-agonist, in unwcightcd musclcs
compared with normal solcus muscles? Therefore, in thc
current study, we investigated the mechanism of enhanced
isoprotcrenol response in unweightcd soleus by comparing
cyclic adcnosinc monophosphate (cAMP) accumulation
following receptor or postreccptor stimulation of normal
and 3-day unweighted or dcncrvatcd musclc. Furthcr com-
parisons of the _-adrencrgic systems in these musclcs were




Female Sprague-Dawley rats (60 to 75 g; Sasco, Omaha, NE)
were maintained on food and water ad libitum. Suspended animals
were tranquilized with Innovar-Vet (l(I _tL/100 g body weight;
Pitman-Moore, Mundelein, ILl and tail-casted as previously de-
scribed?: Control animals remained weight-bearing and were
neither tranquilized nor tail-casted, since neither of these manipu-
lations alters _-adrenergic responses 3 days later. Bilateral dener-
vation of rat hindlimbs was performed under the combined
administration of Innovar-Vet and ether. A small incision was
made in the skin on the posterior aspect of the thigh, and the
overlying muscle tissue was blunt dissected to reveal the sciatic
nerve. A small piece (2 to 3 mm) of the nerve was removed to
prevent nerve regeneration, and the incision was closed with
surgical wound clips. All treatments lasted 3 days.
To be made diabetic, overnight food-deprived rats were injected
intrapcritoneally tIP) with streptozotocin (85 mg/kg body weight,
Sigma Chemical, St Ia)uis, MO) in 0.9% saline. On the mornings of
the third and fourth days after streptozotocin treatment, animals
were injected subcutaneously (SC) with 5 U protamine zinc insulin
(Eli Lilly, Indianapolis, IN) per 10(I g body weight. For suspended
animals, tail-casting wax performed 2 hours after the last insulin
injection, with the animals wrapped loosely in a towel to reduce
stress. Insulin was then withdrawn from all animals so that 72 hours
later the animals were diabetic, as estimated from blood glucose
levels of at least 18 mmol/L. Glucose in deproteinized plasma was
measured spect rophotometrically. 13
cAMP Determinations
Animals were killed by cervical dislocation, and soleus muscles
were excised and weighed. Muscles were preincubated for 3(I
minutes in 3 mL Krebs-Ringer bicarbonate solution (pH 7.4, 37°C)
equilibrated with 95% 02:5% CO., and containing 5 mmol/L
glucose, 5 mmol/L succinate, 4 mmol/L pyruvate, 4 mmol/L
glutamate, 1.5% bovine serum albumin (fatty acid-free) and 10 i.tU
From the Departments of Biochemistry and Physiolobg', College of
Medichw, University of Arizcma, Tac_n, AZ
Supported by National Aeronautics and Space Administration
(NASA) Grant No. NAG2-384 (to M.E.Z), NASA Graduate Re-
searcher Program award (to C.R.K.), National Institutes of Heahh
Training Grants No. NS-07309 and No. ITL-07249 to the D_Tmrtment
of Physiolog3; and Biomedical Research Support Grant No. RR-05675
to the College of Medicine.
Address reprint requests to Mart: E. Tischler, PhD, Department of
Biochemistry, College of Medicine, Universi_ of Arizona, Taeson, AZ
85 724.
Copyright _ 1992 by H(B. Saunders Contparl_,
0026-0495/92/4107-0021503.00/0
Metabolism, Vol 41, No 7 (July), 1992: pp 793-799 793
https://ntrs.nasa.gov/search.jsp?R=19980213326 2020-06-16T00:06:32+00:00Z
794 KIRBYETAL
bovine insulin/mE Muscles were then transferred for lI) minutes
to fresh Krebs-Ringer bicarbonate buffer containing 5 mmol/L
glucose, 25 mmol/L theophylline (to inhibit phosphodiesterase),
1.5% bovine serum albumin (fatty acid-free), and 10 txU bovine
insulin/mL with or without isoproterenol or forskolin (as indicated
in the figures and tables). Insulin was included during incubations
to duplicate conditions used in previous studies that demonstrated
an increased isoproterenol response of glycogen metabolism in
unweighted soleus muscle?
Following incubation, muscles were blotted, frozen in liquid
nitrogen, and homogenized in a Duall tube containing (1.5 mL
acidic ethanol (l mol/L HCl:ethanol, 1:100). Homogenates were
transferred to Eppendorf tubes and centrifuged at 12,(1()0 x g for
15 minutes. The supernatant solution was saved, and the pellet was
washed with 0.5 mL ethanol:water (2:1) and centrifuged for an
additional 10 minutes. Supernatants were combined and evapo-
rated to dryness under a stream of nitrogen at 55°C. The residue
was dissolved in 50 mmol/L TRIS and 4 mmol/L EDTA buffer (pH
7.5), and then frozen at -20°C until assayed. The volume of buffer
(0.1 to 2.0 mL) for dissolving the residue was selected so that a
50-I.tL aliquot of the sample would fall within the range of
maximum sensitivity (0.5 to 4.0 pmol) for the cAMP assay, cAMP
was assayed using a commercial protein-binding kit (Amersham,
Arlington tleights, ILl. Except for bovine insulin (Calbiochem, San
Diego, CA), chemicals were obtained from Sigma.
Intramuscular Injections
Animals were injected intramuscularly (IM) as described previ-
ously H and adapted from Gerard el al. 14 Rats were tranquilized
with Innovar-Vet. Both hindlimbs were shaved and the skin was
swabbed with ethanol. An incision was made through the outside of
the leg, and a curved blunt forceps was used to hook the soleus
muscle. Then, 0.9% saline containing theophylline (62.5 mmol/L)
was injected into the left muscle. The injection for the right muscle
also included either isoproterenol (2.5 txmol/L) or insulin (10
mU/mL). After 20 minutes, the muscles were excised and frozen in
liquid nitrogen. Muscles were homogenized and cAMP content
was determined as described above.
Hormone-Binding Study
Particulate preparations were obtained from muscles frozen in
liquid nitrogen as described by Ligget et al. 15 Muscles were minced
in ice-cold buffer (10 mmol/L TRIS, 5 mmol/L EDTA, pH 7.4) and
homogenized in 20 volumes of the same buffer with a Polytron PI0
(Brinkman lnsts, Westbury, NY) at maximum speed for three
10-second bursts. Homogenates were filtered over nylon mesh (1
mm z) and centrifuged at 37,000 x g for 20 minutes at 4°C. The
pellet was resuspended in the same buffer and washed twice using
similar centrifugations. Final suspensions (_7 mg muscle wet
weight/mL) were in incubation buffer (75 mmol/L TRIS, 25
mmol/L MgCI2, 5 mmol/L EDTA, pH 7.4).
For the binding assay, preparations (100 txL) were incubated for
60 minutes at 25°C with [125I]iodo-(-)-pindolol (2,200 Ci/mmol;
New England Nuclear, Boston, MA) in a final volume of 150 _L
incubation buffer. 15 The reaction was terminated by adding 10 mL
ice-cold incubation buffer and vacuum filtering through a What-
man GF/C glass fiber filter (Whatman International, Maidstone,
England). Filters were washed with an additional 30 mL incubation
buffer, and bound radioactivity was measured in a gamma-counter.
Nonspecific binding was determined by linear regression of binding
that occurred in the presence of 1 ixmol L-propranolol. Specific
binding was calculated as the difference between total and nonspe-
cific binding.
Data Analysis
Receptor densities (Bm_) and apparent dissociation constants
(K,t) were estimated by multiple iterative nonlinear analysis of
saturation binding data using the computer program, LIGAND
(Elsevier-Biosoft, Cambridge, UK). I_' Specific binding expressed
per milligram muscle or per whole muscle was calculated using the
total wet weight of tissue or total number of muscles represented by
the 100-p,L particulate preparation used in the saturation binding
experiments. Testing for significant differences between means
(P < .05) was done by a paired Student's t test or by factorial
ANOVA with a post hoc Schefffi F test or Fisher exact probability
test. Differences in percent effects of isoproterenol or insulin
injections between groups were analyzed by the Mann-Whitney U
test. All results are expressed as means _+ SE for the number of
muscles indicated in each table or figure.
RESULTS
Muscle and Body Masses
Weight-bearing (control) animals weighed approxi-
mately 15 g less initially than unweighted and denervated
animals (Table 1), so that final soleus muscle mass would be
more closely matched for incubations. Masses of muscles
used for cAMP determinations were similar in weight-
bearing and denervated muscles, while those from un-
weighted animals were slightly (6%) smaller. Similar final
muscle size diminished the possibility of different diffusion
distances. Unweighted animals gained less than weight-
bearing or denervated animals. Since food consumption is
similar in unweighted and weight-bearing animals, _2 this
weight-gain difference is likely due to the mild stress effects
associated with tail-cast suspension, t7 In both cAMP accu-
mulation and hormone-binding experiments (not shown),
the ratio of muscle to body mass, an index of muscle
atrophy, was less in unweighted and denervated animals
than in control animals.
cAMP Accumulation In Vitro
One potential mechanism for the greater effects of
isoproterenol on glycogen metabolism in unweighted mus-
cle 4 could be postreceptor alterations, such as in adenylate
cyclase activity. Therefore, we measured accumulation of
cAMP (in the presence of theophylline) following incuba-
tion with or without forskolin, which activates adenylate
cyclase independent of the 13-adrenergic receptor. TM The
only difference detected in basal cAMP accumulation was a
lower (P < .05) amount in unweighted than in denervated
muscle (Table 2). Forskolin treatment increased cAMP
Table 1. Muscle and Body Masses of Animals Used
for cAMP Determinations
Body Mass (g)
Soleus Mass Soleus: Body
Muscle Initial Final (mg) (rag:g)
Normal 61.7 _+ 1.0 76.2 +_ 1.1 29.2 - 0.4 0.383 -+ .009
Unweighted 75.1 _+ 1.1" 86.2 +- 1.1"1" 28.1 -+ 0.4"1" 0.314 -+ .005*
Denervated 76.2 _+ 1.0" 91.6 _+1.0" 28.6 - 0.4 0.312 -+ .004"
NOTE. Values are means _+SE for 42 to 47 animals.
*P < .05 unweighted or denervated versus weight-bearing by
ANOVA.
I"P < .05 unweighted versus denervated by ANOVA.
CYCLIC ADENOSINE MONOPHOSPHATE ACCUMULATION
Table 2. Effect of Forskolin on cAMP Accumulation in Vitro
Forskolin Unweighted
(mmol/L) Normal (pmol/muscle) Denervated
0 8.6 -+ 0.6 7.2 _+0.5* 9.9 +- 0.6
0.1 81.4 _+7.01" 81.6 -+ 5.31" 73.0 _+6.41"
0.3 137.0 -+ 12.51" 138.3 _+ 6.61" 136.7 -+ 11.6t
0.5 169.4 +- 16.21" 137.8 +_ 7.4"1" 192.9 + 10.9t
1.0 178.9 -+ 1.81" 142.8 _+7.0*t 215,2 _+34.01`
NOTE. Muscles were incubated as described in the Methods with 10
_zUinsulin/mL and the forskolin concentration indicated, cAMP accumu-
lation was also measured as described in the Methods. Values are
means -+ SE for 4 to 19 muscles.
*P < .05 unweighted versus denervated by ANOVA.
tP < .05 forskolin versus no forskolin by ANOVA.
accumulation in a dose-dependent manner in all condi-
tions. A maximal effect was achieved at 0.5 mmol/L.
Accumulation of cAMP in normal muscle did not differ
from that in unweighted or denervated muscles at all
forskolin concentrations tested. However, at the higher
concentrations of forskolin, dcncrvated muscle accumu-
lated more cAMP than did unwcightcd muscle. These
results suggest that the site of enhanced isoprotercnol
responsc in the unweightcd solcus is likely proximal to the
adenylate cyclase catalytic subunit in the !3-adrenergic
receptor-effector cascade.
Isoproterenol stimulatcd cAMP accumulation in a dose-
dependent fashion in all three muscles (Fig 1). In accor-
dance with an enhanced isoprotcrenol rcsponse of glycogen
metabolism, 4 cAMP accumulation was markedly greater in
unweighted than in weight-bearing or denervated muscles.
Weight-bearing and dcnervated musclcs showed similar
responses. These differences in cAMP accumulation could
not bc attributcd to variable muscle integrity, as cAMP in
the medium was below the detectable (0.2 pmol) limit
under all conditions. These data suggest an enhanced
isoproterenol sensitivity of cAMP accumulation in un-
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Fig 1. Effect of isoproterenol on cAMP accumulation. Muscles
were incubated as described in Methods with 10 I_U insulin/mL and
the isoproterenol concentration indicated above. Values are means -+
SE for five to 12 muscles. *P < .05 compared with weight-bearing.
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cAMP Accumulation In Vivo
To evaluate the [3-adrenergic response of cAMP accumu-
lation in vivo, solcus muscles were injected with 0.9% saline
containing thcophylline with or without isoprotcrenol (Ta-
ble 3). In the absence of isoprotercnol, cAMP accumulation
was lower (-46%) in unweighted than in weight-bearing
muscles. Injection of isoproterenol elevatcd muscle cAMP
content in both conditions. In agreement with in vitro
results, both the absolute and percent increases of cAMP
accumulation were greater in unweightcd comparcd with
weight-bearing muscles.
A proportionately smaller solution volume had been
injected into the unweighted muscles than into the weight-
bearing muscles. Even so, it was possible that the differen-
tial responses, in part, werc a result of a diffcrcnce in
isoprotcrcnol concentration in the muscle. To estimate the
approximate agonist amount present, we used the percent
in vivo responses from Table 3 and the in vitro dose curve in
Fig 1 to predict the approximate average isoproterenol
concentration in these muscles. For both control and
unweighted muscles, a concentration of 0.24 ixmol/L was
estimated. Thus, the difference reporlcd in Tablc 3 was
characteristic of the muscles, and was not a consequence of
some large difference in agonist concentration.
In vivo basal cAMP accumulation was significantly less in
unweighted muscle (Table 3). Since the insulin sensitivity of
unweighled soleus is increased t and insulin reportedly
reduces cAMP levcls in some tissues, =_,2° we tested in vivo
whether insulin effects could account for the basal differ-
ence in cAMP accumulation. Thus, unwcightcd or wcight-
bcaring musclcs of diabctic animals wcrc injected with
thcophyllinc with or without insulin (Table 4). Diabetic
animals wcrc used to abolish the potential influence of
circulating insulin on muscle cAMP levels. Elimination of
insulin abolished the difference in cAMP accumulation
detected in the absence of isoprotercnol (Table 3). Injec-
tion of insulin significantly reduced the accumulation of
cAMP in both conditions, but produced an even greater
Table 3. Effect of Isoproterenol on cAMP Accumulation In Vivo
Amount of cAMP (pmol/muscle)
Muscle No Isoproterenol With Isoproterenol Increase {%)
Weight-bearing 10.0 -+ 1.7 40.9 ± 3.1" 309 -+ 70
Unweighted 5.4 _+0.5t 53.7 ± 4.1"1" 894 +_114:1:
NOTE. Contralateral soleus muscles in eight weight-bearing or
hindlimb-suspended animals were injected with theophylline with or
without isoproterenol as described in the Methods. Weight-bearing
muscles were injected with 4.0 #L/100 g body weight, but unweighted
muscles were injected with only 3.2 t_L/IO0 g body weight to account
for muscle size differences owing to atrophy caused by unweighting,
These volumes are based on average soleus muscle sizes of 40 and 32
rag/100 g body weight for weight-beating and suspended animals,
respectively. After 20 minutes, the muscles were excised and immedi-
ately processed for analysis of cAMP accumulation as described in the
Methods. Results are means + SE.
*P < .001 isoproterenol versus no isoproterenot by ANOVA or paired
t test.
tP < .05 unweighted versus weight-bearing by ANOVA.
¢P < .001 unweighted versus weight-bearing by Mann-Whitney.
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Table 4. Effect of Insulin on cAMP Accumulation In Vivo
Amount of cAMP {pmol/muscle)
Muscle Without Insulin With Insulin Decrease (%)
Weight-bearing 9.4 -+ 0.8 5.3 -+ 0.4* 41.5 -+ 5.9
Unweighted 11.3 -+ 1.2 3.8 -+ 0.4* 65.8 ± 2.1t
NOTE. Muscles from diabetic rats were injected with theophylline
with or without insulin, as in Table 3. Weight-bearing muscles were
injected with 3.7 _L/100 g body weight, and unweighted muscles were
injected with 2.7 p.L/100 g body weight. Volumes are based on average
soleus muscle sizes of 37 and 27 mg/1O0 g body weight for weight-
bearing and suspended diabetic animals, respectively. Results are
means +- SE,
*P < .01 insulin versus no insulin by ANOVA or paired t test.
1-P < .001 unweighted versus weight-bearing by Mann-Whitney.
effect in the unweighted muscle, thereby restoring a signifi-
cant difference, as between muscles of nondiabetic animals
(see Tables 3 and 4).
_Adrenergic Binding
To distinguish between altered hormone sensitivity and
responsiveness, we measured the binding capacity of the
membrane receptor. [l_I]iodo-(-)-pindolol saturation bind-
ingwas measured with particulate preparations from weight-
bearing, unweighted, and denervated muscles. Binding
appeared saturable and could be inhibited by 1 txmol
L-propranolol. Specific binding occurred in "zone A" (ie,
< 10% of total ligand bound) and represented between
70% to 90% of total maximal binding (Fig 2). Scatchard
analysis 2t of binding data demonstrated similar receptor
affinity (Ka) for weight-bearing (20.7 ± 1.9 pmol/L), un-
weighted (25.8 ± 3.3 pmol/L), and denervatcd (20.3 - 2.1
pmol/L) muscles (Fig 3). These values agree with the Kj
(19.5 pmol/L) in [125I]iodo-(-)-pindolol binding in human
skeletal muscle. _5 Maximal binding capacity per mg muscle
was markedly greater in the unweighted soleus compared
with the weight-bearing and denervated muscles that yielded
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Fig 2. p_l]iodo-(-)-pindolol binding to weight-bearing soleus
particulate preparations. Muscles were treated as described in Meth-
ods. Data points represent mean values from triplicate determina-
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Fig 3. Scatchard analysis of pZSlliodo-{-)-pindolol binding to par-
ticulate preparations from weight-bearing and 3-day unweighted or
denervated muscles, Muscles were treated as described in Methods.
Lines of best fit were computed by nonlinear regression as described
in Methods. Each point represents the mean +- SE of triplicate
determinations from three or four separate experiments; emol =
10 -_s mol.
muscle, maximal binding capacity was lower in denervated
(7.8 _ 1.1 fmol/muscle) than in weight-bearing (11.2 ± 0.8
fmol/muscle) or unweighted (11.5 - 1.2 fmol/muscle) mus-
cles. Similar general findings were obtained for binding of
[3H]dihydroalprenolol to membrane preparations from these
muscles. 22 These results suggest that the increase in [3-recep-
tor number per mg muscle in unweighted soleus must be
mostly a consequence of muscle atrophy and not of an
increase in the total receptor population. The reduction in
total [3-receptors of denervated muscle suggests that the
loss of this membrane protein parallels decreases in struc-
tural proteins.
DISCUSSION
Receptor and Postreceptor Stimulation of cAMP
Accumulation
Hormone effects can be characterized by altered sensitiv-
ity or responsiveness representing receptor or postreceptor
modifications, respectively) -_ Investigation herein of recep-
tor and postreceptor stimulation of the [3-adrenergic recep-
tor-effector cascade supported our previous studies that
suggcsted greater 13-adrenergic sensitivity following un-
weighting. 4 Whether via incubation (Fig 1) or IM injection
(Table 3), submaximal amounts of isoproterenol increased
cAMP accumulation more so in unweighted muscle. Similar
responses to maximal amounts of isoproterenol were in
accordance with enhanced sensitivity, z3 This concept is
further supported by the comparable postreceptor stimula-
tion by forskolin of cAMP accumulation in unweighted and
weight-bearing musclcs (Tablc 2). Thus, increased respon-
siveness of adenylate cyclase cannot account for enhanced
[3-adrenergic effects in unweighted muscle.
These results cannot exclude enhanced G-protein-
complex coupling between the receptor and adenylate
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cyclase. For instance, decreased isoproterenol response of
cardiac muscle from adrenalectomized animals occurs with-
out altered [3-receptor density or affinity. 24 Instead, the lack
of glucocorticoids may alter 13-adrenergic responses at a
postreceptor site. As dexamethasone treatment reverses
reductions in the G_-protein subunit mRNA of adipocytes
from adrenalectomized rats and increases this mRNA in
normal animals, glucocorticoids may modulate [3-adrener-
gic receptor-effector coupling. 25 The several-fold increases
of plasma glucocorticoids _7 and soleus glucocorticoid recep-
tors 2_'foflowing unwcighting could possibly alter the [3-ad-
renergic receptor-effector cascade. Further studies are
needed to evaluate this possibility.
A possible role of systemic effects in altered hormone
responses of unweighted versus weight-bearing muscles has
been evaluated by examining insulin and isoproterenol
responses of the extensor digitorum longus, a hindlimb
muscle unaffected by hindlimb unweighting. Insulin stimu-
lation of glucose transport _-3and isoproterenol stimulation
of lactate production 4 were similar in this muscle from
control and suspended animals. Therefore, differences in
hormone responses between weight-bearing and un-
weighted soleus muscles are not likely due to a systemic
alteration.
In our earlier study, 4 incubations contained physiological
amounts of insulin to assess insulin antagonism of isoproter-
enol effects in unweighted or dcnervated muscles. The
insulin resistance of carbohydrate metabolism in dener-
vated muscle TM prevented us from evaluating this question.
Results from the current study clearly indicate that neither
receptor- nor postreceptor-mediated stimulation of cAMP
accumulation is altered 3 days after denervating the soleus
(Table 2 and Fig 1). These results agree with the similar
forskolin-stimulated adenylatc cyclase activity and [3H]for-
skolin binding in 10-day dencrvatcd gastrocnemius. -_7 In
contrast, a 5()_ decline in basal and catecholamine- or
fluoride-stimulated adenylate cyclase activity occurred for a
mixture of hindlimb muscles denervated for 5 days. 2_ This
decrease was attributed to reduced amounts of adcnylate
cyclase enzyme per muscle. The reason for the discrepancy
between these two studies is unclear. Possibly, the absence
of phosphodiesterasc inhibitors in one study 2_ confounds
the specific determination of differences in adcnylate cy-
clase activity.
Insulin Effects on cAMP Accumulation
Previous studies reported increased effects of insulin on
carbohydrate and protein metabolism in unweighted mus-
cle. 1,7,z_ Additionally, the greater insulin sensitivity of un-
weighted muscle leads to a lower accumulation of cAMP
(Table 4). To our knowledge, this is the first investigation to
demonstrate a reduced accumulation of cAMP in skeletal
muscle following insulin treatment.
Several investigations have demonstrated an increased
production of intracellular insulin mediators following
insulin treatment of skeletal muscle. 3_-32These mediators
increase the activity of low-Km phosphodiesterase and
decrease adenylatc cyclase activity in adipocyte and hcpato-
cyte membranes. 32-34However, neither in vitro, in viw), nor
in situ insulin treatment diminished skeletal muscle cAMP
levels in previous studies. 35,-_ In this investigation, an effect
of intracellular insulin mediators on phosphodiesterase
activity was unlikely, as theophylline was always present.
However, these results are consistent with insulin antago-
nism of isoproterenol-stimulated lactate formation in mus-
cle. 4.37 While these findings support a response of cAMP
metabolism to insulin in muscle, they cannot exclude
possible insulin effects at sites other than adenylate cyclase.
For example, insulin inhibition of cAMP-dependent pro-
tein kinase activity 3s could also explain the diminished
formation of lactate.
The inability of previous investigators to detect insulin
effects on muscle cAMP metabolism could be due to the
absence of phosphodiesterase inhibitors in those stud-
ies. 35,3_ Furthermore, the use of muscles from diabetic
animals may allow detection of small differences in cAMP
accumulation due to insulin. While the physiologic signifi-
cance of these responses remains to be deterv fined, small
changes in skeletal muscle cAMP levels by insulin could
possibly result in large changes in cellular metabolism
through amplification.
[3-Adrenergic Binding Capacity in Atrophic Soleus
In accordance with the concept that altered hormone
sensitivity is a receptor-mediated phenomenon, 23 [3-adren-
crgic binding capacity increased during unweighting atro-
phy (Fig 3). Just as increased effects of insulin paralleled
greater insulin binding capacity in unweightcd solcus, 1,-'_
enhanced isoproterenol effects in unweightcd muscle can
be attributed to increased [3-adrenergic-receptor concentra-
tion. Mechanisms for increased [?,-receptor density may
include: (1) up-regulation due to reduced circulating cate-
cholamines3_; (2) changes in plasma glucocorticoids, which
induce 13-receptor expression4_; or (3) sparing of membrane
receptors during unwcighting atrophy. _ Catecholaminc-
induced up-regulation of the [3-receptor seems unlikely, as
plasma catecholamines increase during the first several
days of suspension? nAs we did not detect an increase in the
total receptor population, it is not likely that increased
plasma glucocorticoids Iv induced [3-receptor expression
during unwcighting. However, these data cannot exclude a
role for glucocorticoids in maintaining 13-receptors during
unweighting atrophy. Just as for insulin receptors, t there
are a similar number of [?,-receptors per whole unweighted
or weight-bearing muscle. Thus, the increase in receptor
density per mg muscle must result from preferential loss of
structural proteins rather than from up-regulation. It is
noteworthy that the percent increase in [3-adrenergic recep-
/7'ttors (46 _c) (Fig 3) and insulin receptors (50%) 1agree.
Isoproterenol responses of cAMP accumulation (Fig 1)
and [I251]iodo-(-)-pindolol binding capacity per milligram
muscle (Fig 3) were similar in denervated and innervated
soleus muscles. The reduced total binding capacity (fmol/
muscle) following denervation suggests that receptor and
nonrcceptor proteins are lost proportionately, thus preserv-
ing a receptor density comparable to innervated muscle.
This constancy of [3-adrenergic binding capacity was also
evident in a mixed hindlimb muscle membrane preparation
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following 5 days of denervation. 28 This similar [3-adrenergic
binding capacity in innervated and denervated muscles
parallels their similar insulin binding capacity. 5 These
results support the concept that, even though both un-
weighted and dcnervated muscles undergo atrophy, ccrtain
hormone responses and receptor binding capacitics diffcr
distinctly in these models of reduced use.
Mechanisms of Proteolysis in Un weighted and Denervated
Soleus
A principal goal of studies from our laboratory has bccn
to evaluate the possibility of different mechanisms of
proteolysis in unweighted and denervated soleus muscles. I1
Recent evidence suggests that membrane receptors may be
degraded primarily through lysosomal proteolysisY ,_° Thus,
sparing of insulin reccptors in unweighted, j but not in
denervated, _ muscle supports the idea that lysosomal prote-
olysis plays a greater role in denervation than in unweight-
ing atrophy. Accordingly, IM injection of chloroquine, a
lysosomotropic agent, diminished atrophy and in vivo prote-
olysis of the dcnervated, but not of the unweightcd, soleus
muscle.ll The finding here of increased [3-adrenergic recep-
tor density with unweighting, but not with dcnervation,
atrophy also supports this hypothesis.
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